The new MT Cap technology is designed to provide a target location and guides the identification of a patient’s motor threshold (MT)
NeuroStar is a TMS treatment intended for major depressive disorder. (Credit: VSRao from Pixabay)
Neuronetics has received the US Food and Drug Administration (FDA) 510(k) clearance for MT Cap technology to be used for its ‘NeuroStar Advanced Therapy for Mental Health’.
NeuroStar Advanced Therapy for Mental Health is a TMS (transcranial magnetic stimulation) treatment intended for major depressive disorder.
It is a non-drug, non-invasive treatment that works by stimulating neurons in the area of the brain that controls mood and does not need general anaesthesia or sedation.
Neuronetics said that the components and software used in NeuroStar are designed to precisely deliver the recommended treatment dose.
The new MT Cap technology is designed to provide an initial target location and guides the identification of a patient’s motor threshold (MT).
It leverages NeuroStar’s floating coil locking system for determining MT and is said to reduce the multiple steps involved in the initial assessment.
Neuronetics clinical affairs and medical operations VP Cory Anderson said: “We’re delighted to bring to market this latest in a series of technologies designed to make the motor threshold determination process simpler and more efficient for clinicians.”
According to the company, determining and locating the patients’ MT is an important step in the treatment process, and may require up to 30 minutes for each patient.
New MT Cap, when combined with the recently launched Fast MT technology, is claimed to provide average time savings of 40% during the MT activity.
Neuronetics intends to commence a limited launch of the technology within a few weeks and is planning to roll out the product in the US, in Q1 2022.
The US-based medical device maker is focused on designing, developing, and marketing non-invasive products for patients with psychiatric disorders.
According to the company, NeuroStar is widely researched and supported by the largest clinical data set, including the world’s largest depression Outcomes Registry.
In March last year, Neuronetics received the FDA breakthrough device designation for its NeuroStar advanced therapy system to treat bipolar depression.